Aandelen in “Tandheelkundige laboratoria”

Aandeel Datum Koers Evolutie
vlag Exagen Inc 23/06 4,355 USD
-1,47% 		-1,47%

Nieuws over “Tandheelkundige laboratoria”

14:52 · Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing · Persbericht

14:52 · Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing · Persbericht

10:26 · Norges Bank - Form 8.3 - Integrated Diagnostics Holdings plc · Persbericht

22/06 · Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test · Persbericht

18/06 · UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics · Persbericht

17/06 · Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 · Persbericht

16/06 · Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report · Persbericht

15/06 · AMN Healthcare Names New Chief Commercial Officer and Chief People Officer to Advance Growth and Culture · Persbericht

29/05 · Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer · Persbericht

28/05 · Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects · Persbericht

27/05 · Labcorp to Present at the Jefferies Global Healthcare Conference · Persbericht

26/05 · PHSC Plc - Trading Update · Persbericht

20/05 · Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time · Persbericht

19/05 · Quest Diagnostics Declares Quarterly Cash Dividend · Persbericht

12/05 · Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems · Persbericht

30/04 · Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance · Persbericht

29/04 · Concord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025 · Persbericht

27/04 · Quest Diagnostics Prices $500 Million of Senior Notes · Persbericht

22/04 · Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA® · Persbericht

21/04 · Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 · Persbericht

16/04 · City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers · Persbericht

Mijn selecties